Conclusions
In conclusion, the results of this analysis indicate that FTD/TPI administered as third- or later-line treatment in patients with mGC/GEJC improved survival and daily functioning outcomes compared with placebo regardless of prior treatment. OS, PFS, and time to ECOG ≥ 2 trended longer in patients who had not previously received IRI, RAM, or PAC. FTD/TPI was tolerable regardless of the type of previous therapy patients had received.